Costco Wholesale Corp. (NASDAQ:COST) announced on Thursday it will not sell abortion pill mifepristone across its U.S. pharmacy locations, citing insufficient member demand amid mounting pressure from religious activist groups targeting major retailers.

Check out the current price of COST stock here. 

Low Demand Drives Business Decision

The warehouse retailer stated its position remains unchanged based on the lack of customer interest, Reuters reported.

“Our position at this time not to sell mifepristone, which has not changed, is based on the lack of demand from our members and other patients, who we understand generally have the drug dispensed by their medical providers,” Costco said.

See Also: Marjorie Taylor Greene Keeps Buying UnitedHealth Stock Along With Fellow Investors Buffett And Burry

Religious Groups Shift Focus To CVS, Walgreens

These groups now target Walgreens Boots Alliance Inc. (NASDAQ:WBA) and CVS Health Corp. (NYSE:CVS), which dispense mifepristone in states where abortion remains legal, according to the report.

“Many retailers have become more cautious about taking overt political or social stances after recent controversies triggered boycotts, negative media coverage, and polarized consumer reactions,” said Arun Sundaram, senior analyst at CFRA.

Supreme Court Ruling

Market Impact

Costco closed at $972.04 on Friday, down $3.35 or 0.34%, with shares trading between $867.16 and $1,078.23 over the past year, according to Benzinga Pro data.

The company has a market capitalization of $431.08 billion, a price per earnings ratio of 55.14, and averages 2.14 million shares in daily volume.

Benzinga’s Edge Stock Rankings for COST stock indicate that the medium-term shows a downtrend, while both the short-term and long-term indicate upticks. Find out how the stock competes with other companies.

Read Next: 

• Neuberger Berman Expands Active ETF Lineup With Emerging Markets Debt Play

Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Photo courtesy: bluestork / Shutterstock.com